معرفی
Professor Supratik Basu is a Professor of Haematology at the University of Wolverhampton, Faculty of Science and Engineering, and serves as a Consultant Haematologist at Royal Wolverhampton NHS Trust. He holds dual clinical and academic leadership roles, including Research Lead for Haemato-Oncology and Haematology Speciality Lead for the National Institute for Health Research (NIHR) in the West Midlands. He is also an Honorary Senior Lecturer with Cancer Research UK and actively collaborates with institutions including the University of Birmingham, Manchester, Oxford, and Southampton.
- MBBS, University of Calcutta (1982)
- MD, University of Calcutta (1982)
- MRCP, Royal College of Physicians, London (1988)
- FRCP, Royal College of Physicians (1988)
- FRCPath, Royal College of Pathologists (2002)
His research centers on malignant haematology, particularly multiple myeloma, with a focus on the bone marrow microenvironment, metabolic interactions, drug development, and improving early diagnosis. He leads translational research projects investigating PADI2, SUCLA2, T cell metabolism, and novel therapeutic combinations. His work bridges clinical practice and laboratory science, aiming to improve patient outcomes through targeted therapies and diagnostic innovations.
His recent publications highlight a strong trend in immunotherapy (e.g., daratumumab, isatuximab), real-world clinical outcomes, metabolic immunosuppression in myeloma, and the development of diagnostic algorithms to differentiate myeloma from MGUS. His studies frequently appear in high-impact journals such as Nature Medicine, Leukemia, and Blood, reflecting his leadership in clinical trials and translational research.
Professor Basu has received significant scientific recognition and funding:
- Fellow of the Royal College of Physicians (FRCP)
- Fellow of the Royal College of Pathologists (FRCPath)
- John Goldman Fellowship (2018)
- CRUK Grant (2017) on PADI2 in myeloma
- CRUK Grant (2008) on marrow fibroblasts
- NIHR and NCRI grants for clinical trials and feasibility studies
He is Chief Investigator for the international MAIA trial and Principal Investigator for over 40 industry and NCRN trials. He supervises PhD research, particularly in collaboration with the University of Wolverhampton, and leads a multi-institutional research network focused on myeloma. His lab and team work closely with immunologists, oncologists, and data scientists to develop predictive models and improve therapeutic strategies for patients with multiple myeloma.
